No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Healthcare Information Services
Indegene Limited operates as a global commercialization partner within the life sciences sector. The company assists biopharmaceutical, nascent biotechnology, and medical device organizations throughout their product's journey, from initial development and market introduction to sustained growth and impact. Its comprehensive offerings include a range of enterprise solutions for commercial, medical, and clinical operations, advanced omnichannel activation strategies, and its proprietary NEXT technology platforms. Established in 1998, the company maintains its headquarters in Bengaluru, India.
www.indegene.comNo one on the platform currently holds INDGN.BO.
No tracked institution reports a position in INDGN.BO as of their last filing.
No one on the platform has traded INDGN.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.0% | 23.8% | — | — | — | |
| Rev. Growth % | 23.6% | 29.4% | ||||
| Profit Margin % | 11.4% | 12.0% | ||||
| Free Cash Flow Margin % | 17.6% | 14.5% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $44.3B | +25.7% | $23.74 | $21.26–$25.64 | — | 7 |
| 2028 | $49.8B | +12.4% | $29.24 | $26.03–$30.44 | — | 7 |
| 2029 | $56.6B | +13.6% | $31.40 | $29.02–$33.51 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $4.63 | $4.80 | +3.7% |
| 2026-04-29 | $4.55 | $3.90 | -14.3% |
| 2026-01-29 | $5.15 | $4.30 | -16.5% |
| 2025-10-30 | $4.65 | $4.20 | -9.7% |
| 2025-07-31 | $5.00 | $4.80 | -4.0% |
| 2025-04-28 | $5.10 | $4.90 | -3.9% |
| 2025-01-30 | $4.60 | $4.60 | +0.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| INDGN.BOIndegene Limited | $571.45 | -2.06% | $137.8B | — |
| BLUEJET.BOBlue Jet Healthcare Limited | $550.80 | -3.05% | $95.2B | — |
| BLUEJET.NSBlue Jet Healthcare Limited | $550.65 | -3.15% | $95.5B | — |
| CAPLIPOINT.NSCaplin Point Laboratories Limited | $2570.60 | -6.69% | $195.4B | — |
| GRANULES.BOGranules India Limited |
| $872.50 |
| -4.08% |
| $217.2B |
| — |
| GRANULES.NSGranules India Limited | $872.60 | -4.04% | $216.2B | — |
| JUBLINGREA.NSJubilant Ingrevia Limited | $630.50 | -4.24% | $99.4B | — |
Source: Financial Modeling Prep · peers by sector/industry